Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trivalent influenza virus split vaccine + ZFA02 adjuvant
- Development stage
- Preclinical
- Lead developer
- Zhifei Biological
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The trivalent influenza virus split vaccine + ZFA02 adjuvant is an investigational adjuvanted split-virus influenza vaccine being developed by Zhifei Biotech (specifically its wholly-owned subsidiary, Anhui Zhifei Longcom Biologic Pharmacy). It is designed for the prevention of seasonal influenza caused by vaccine-related influenza virus strains (typically influenza A/H1N1, A/H3N2, and influenza B/Victoria). The vaccine combines inactivated, split influenza virus antigens with Zhifei's proprietary ZFA02 adjuvant, which is formulated to enhance strain-specific humoral and cellular immune responses against the hemagglutinin (HA) antigens. In April 2025, the vaccine received clinical trial approval (IND approval) from the National Medical Products Administration (NMPA) in China.
- Other names
- Influenza Vaccine (Split Virion), Inactivated, Trivalent (ZFA02 Adjuvant)Trivalent Influenza Split Vaccine, ZFA02 AdjuvantZFA02-adjuvanted trivalent influenza vaccineZFA-02-adjuvanted trivalent influenza vaccineZFA 02-adjuvanted trivalent influenza vaccinetrivalent influenza virus split vaccine (ZFA02 adjuvant)三价流感病毒裂解疫苗（ZFA02佐剂）佐剂三价流感疫苗
02
Targets
HA0 (Influenza B virus hemagglutinin)
Beyond the preview
Go deeper on trivalent influenza virus split vaccine + ZFA02 adjuvant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trivalent influenza virus split vaccine + ZFA02 adjuvant.